{"id":"placebo-ga-0034","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, GA-0034 contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of investigational drugs by isolating the true pharmacological effects from placebo response.","oneSentence":"Placebo (GA-0034) is an inert control substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:37.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT00681538","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2008-01","conditions":"Spasticity, Multiple Sclerosis","enrollment":572},{"nctId":"NCT01361607","phase":"PHASE3","title":"Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-05-27","conditions":"Pain, Advanced Cancer","enrollment":399},{"nctId":"NCT01424566","phase":"PHASE3","title":"A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2012-06-29","conditions":"Pain, Advanced Cancer","enrollment":406},{"nctId":"NCT01262651","phase":"PHASE3","title":"Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer","status":"COMPLETED","sponsor":"GW Pharmaceuticals Ltd","startDate":"2010-11-25","conditions":"Pain, Advanced Cancer","enrollment":397},{"nctId":"NCT01868048","phase":"PHASE3","title":"Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.","status":"WITHDRAWN","sponsor":"GW Research Ltd","startDate":"","conditions":"Spasticity, Multiple Sclerosis","enrollment":""},{"nctId":"NCT00391079","phase":"PHASE3","title":"Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS","status":"COMPLETED","sponsor":"GW Pharmaceuticals Ltd","startDate":"2006-09","conditions":"Multiple Sclerosis","enrollment":339}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (GA-0034)","genericName":"Placebo (GA-0034)","companyName":"GW Pharmaceuticals Ltd","companyId":"gw-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}